Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clenbuterol/nadolol - CuraSen Therapeutics

Next Previous
X
Search
Drug Profile

Clenbuterol/nadolol - CuraSen Therapeutics

Alternative Names: CLENBUTEROL HYDROCHLORIDE/CST-107; Clenbuterol hydrochloride/nadolol - CuraSen Therapeutics; CST-103/CST 107

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CuraSen Therapeutics
  • Class Alcohols; Amines; Antidementias; Antihypertensives; Antimigraines; Chlorobenzenes; Class II antiarrhythmics; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Beta adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dementia; Mild cognitive impairment; Sleep disorders

Most Recent Events

  • 03 Jul 2024 CuraSen Therapeutics withdrew prior to enrollment a phase II trial in Parkinson's disease (Combination therapy) in Australia (PO), due to a sponsor's decision (NCT04935762)
  • 31 Mar 2023 Safety and efficacy data from a phase II trial was released by CuraSen Therapeutics .
  • 30 Mar 2023 CuraSen Therapeutics plans phase II CLIN-012 trial for Parkinson's Disease in Australia (PO, Capsule) in June 2023 (NCT04935762)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top